{
    "clinical_study": {
        "@rank": "89216", 
        "arm_group": {
            "arm_group_label": "biomarker group", 
            "description": "Metastatic cancer undergoing genomic profiling"
        }, 
        "biospec_descr": {
            "textblock": "fresh tissue"
        }, 
        "biospec_retention": "Samples With DNA", 
        "brief_summary": {
            "textblock": "The next generation of personalized medical treatment according to the type of personal\n      genetic information are evolving rapidly. The genome analysis needs systematic infra and\n      database based on personal genetic information Therefore, a big data of genome-clinical\n      information is important.\n\n      To determine the feasibility of the use of tumor's molecular profiling and targeted\n      therapies in the treatment of advanced cancer and to determine the clinical outcome(PFS,\n      duration of response and overall survival) of patients with advanced cancer, the\n      investigators are going to take a fresh tissue of patients and process molecular profiling\n      and receive molecular profile directed treatments."
        }, 
        "brief_title": "NEXT1 Trail [ N of 1 pErsonalized tX(Therapy) With mulTi-omics and Preclinical Model]", 
        "completion_date": {
            "#text": "January 2020", 
            "@type": "Anticipated"
        }, 
        "condition": "Metastatic Cancer", 
        "condition_browse": {
            "mesh_term": [
                "Neoplasm Metastasis", 
                "Neoplasms", 
                "Neoplasms, Second Primary"
            ]
        }, 
        "detailed_description": {
            "textblock": "same as above"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  pathologically confirmed malignancy\n\n        Exclusion Criteria:\n\n          -  patients who do not agree with biopsy\n\n          -  patients who do not have enough tissue for acquisition"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "20 Years", 
            "sampling_method": "Probability Sample", 
            "study_pop": {
                "textblock": "patients with treatment-refractory malignancy"
            }
        }, 
        "enrollment": {
            "#text": "500", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "February 10, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02141152", 
            "org_study_id": "2013-10-017"
        }, 
        "is_fda_regulated": "No", 
        "lastchanged_date": "May 14, 2014", 
        "location": {
            "contact": {
                "email": "jyun.lee@samsung.com", 
                "last_name": "Jeeyun Lee, MD", 
                "phone": "+82-10-9933-1779"
            }, 
            "facility": {
                "address": {
                    "city": "Seoul", 
                    "country": "Korea, Republic of", 
                    "zip": "99999"
                }, 
                "name": "Samsung Medical Center"
            }, 
            "investigator": {
                "last_name": "Jeeyun Lee, Professor", 
                "role": "Sub-Investigator"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "Korea, Republic of"
        }, 
        "number_of_groups": "1", 
        "official_title": "NEXT1 Trail [N of 1 pErsonalized tX(Therapy) With mulTi-omics and Preclinical Model]", 
        "other_outcome": [
            {
                "description": "Changes in the tumor's molecular profile on serial biopsies (when feasible)", 
                "measure": "a Measure of Safety and Tolerability", 
                "safety_issue": "No", 
                "time_frame": "From date of start of targeted treatment oriented by NEXT until the date of first progression or date of death from any cause, whichever came first, assessed up to 1 year"
            }, 
            {
                "description": "To establish n of 1 preclinical model for each patient", 
                "measure": "A Measure of Safety and Tolerability", 
                "safety_issue": "No", 
                "time_frame": "From date of start of targeted treatment oriented by NEXT until the date of first progression or date of death from any cause, whichever came first, assessed up to 1 year"
            }
        ], 
        "overall_contact": {
            "email": "jyun.lee@samsung.com", 
            "last_name": "Jeeyun Lee, MD", 
            "phone": "82-10-9933-1779"
        }, 
        "overall_official": {
            "affiliation": "Division of Hematology-Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea", 
            "last_name": "Won Ki Kang, MD", 
            "role": "Study Chair"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Korea: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "September 2016", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "The feasibility of the use of tumor's molecular profiling and targeted therapies in the treatment of advanced cancer", 
            "measure": "feasibility", 
            "safety_issue": "No", 
            "time_frame": "From date of start of targeted treatment oriented by NEXT until the date of first progression or date of death from any cause, whichever came first, assessed up to 1 year"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02141152"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "The PFS(progression Free survival) of patients with advanced cancer who undergo molecular profiling and receive molecular profile directed treatments", 
                "measure": "Progression Free Survival", 
                "safety_issue": "No", 
                "time_frame": "1years"
            }, 
            {
                "description": "The duration of response of patients with advanced cancer who undergo molecular profiling and receive molecular profile directed treatments", 
                "measure": "duration of response", 
                "safety_issue": "No", 
                "time_frame": "1years"
            }, 
            {
                "description": "The overall survival of patients with advanced cancer who undergo molecular profiling and receive molecular profile directed treatments", 
                "measure": "overall survival", 
                "safety_issue": "No", 
                "time_frame": "1years"
            }
        ], 
        "source": "Samsung Medical Center", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Samsung Medical Center", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "February 2014", 
        "study_design": "Time Perspective: Prospective", 
        "study_type": "Observational", 
        "verification_date": "January 2014"
    }
}